

Date: May 14, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Submission of Media Release

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Audited Consolidated and Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026 duly approved by the Board of Directors of the Company in their meeting held on May 14, 2026.

You are requested to take the same on your record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosure: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com




W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

SENORES PHARMACEUTICALS LIMITED




Strong Financial & Operational Performance for Q4 & FY26

Ahmedabad, Gujarat, 14th May 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its Audited Financial Results for the 4th Quarter and Full year ended 31st March 2026.

Q4 & FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS

Total Income Rs. 190 Crs.  +66% Y-o-Y for Q4FY26	EBITDA Rs. 62 Crs.  +219% Y-o-Y for Q4FY26	PAT Rs. 37 Crs.  +104% Y-o-Y for Q4FY26
--	---	---

FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS

Total Income Rs. 664 Crs.  +65% Y-o-Y for FY26	EBITDA Rs. 200 Crs.  +114% Y-o-Y for FY26	PAT Rs. 122 Crs.  +108% Y-o-Y for FY26
---	--	--

Q4 & FY26 SEGMENTAL HIGHLIGHTS

Segment Revenue (INR Cr)	Q4FY26	Q4FY25	Y-O-Y	FY25	FY26	Y-o-Y
Regulated Markets	117.8	43.8	169.0%	427.4	224.3	90.6%
Emerging Markets	49.5	46.8	5.7%	148.6	131.4	13.1%
Branded Generics	9.4	4.0	132.4%	40.0	8.2	385.3%
Other Op. Income	13.1	19.6	-33.6%	48.1	37.7	27.3%
Total Income	189.7	114.3	66.0%	664.0	401.7	65.3%

FY26 FINANCIAL & BUSINESS HIGHLIGHTS

✓ **Strong Improvement in Cash Flow Operations**

- Cash Flow from Operations for FY26 stood at Rs. 75 crs, showing significant improvement over last year. EBITDA-to-Operating Cash Flow conversion has improved too.

✓ **Robust product pipeline for Regulated Markets**

- 51 approved ANDAs covering 151 strengths, with over 30 ANDAs yet to be launched and 27 additional ANDAs under development with 65+ strengths, providing strong growth visibility for our regulated business in the coming years

✓ **Emerging Markets on Steady Trajectory**

- The Emerging Markets business on a steady growth trajectory in FY26, with revenue growing by approximately 13% year-on-year. EBITDA margin stood at approximately 12% for FY26, Supported by an increasing focus on niche products,

✓ **Strong Growth in Branded Generics business**

- Branded Generics revenue grew ~385% on Y-o-Y basis for FY26. Portfolio have received approvals from top multi-specialty and specialty hospitals, further strengthening Senores' branded generics business

✓ **Acquisition of Zoraya Pharmaceuticals**

- Entered into to acquire a 51% membership interest in Zoraya Pharmaceuticals, LLC, USA-based entity. Zoraya is being established as strategic initiative to strengthen vertical integration, from the acquired ANDA portfolio to be commercialized under the Zoraya platform, which will serve as a dedicated market-facing brand.

✓ **Acquisition of Apnar Pharmaceuticals**

- Phase 1 – 75% stake acquisition completed; Phase 2 – Balance 25% to be completed by Q2FY27. Revenue begins to flow through. Expect scale up to peak revenue in next 12-18 months

✓ **Entered U.S. Federal Market via Strategic JV**

- Entered into a 70% joint venture, Amerisyn, in the U.S., creating a direct pathway to supply pharmaceuticals to federal, veterans, and defense sectors. This move opens access to a high entry barrier market and is expected to drive future growth by leveraging the company's manufacturing and product capabilities globally.

Commenting on the FY26 performance, **Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“We have delivered a robust performance across segments in FY26, driven by operational discipline, consistent execution, and strong momentum in key growth areas despite an uncertain operating environment.

In the Regulated Markets, our approved ANDA portfolio has more than doubled during the year, increasing from 26 ANDAs as of March 2025 to 51 ANDAs as of March 2026, reflecting the scale and pace of our execution. Out of these, 30 approved ANDAs are yet to be commercialized. Additionally, we have 27 more molecules, involving 65+ unique strengths, at different stages of development. This gives us a strong pipeline of products which are expected to be rolled out over the coming years.

We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharmaceuticals. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth. We have commenced product rollouts from the Apnar facility, with initial revenues starting in Q4FY26. While contributions are currently modest, we expect the facility to scale meaningfully and emerge as a key growth driver over the next 12–18 months.

In Q3FY26, we acquired Zoraya Pharmaceuticals as a step-down subsidiary to strengthen our U.S. marketing and distribution capabilities, enabling direct commercialization of strategic pharmaceutical products in the market.

In April 2026, we entered into a joint venture, Amerisyn, marking a key milestone for our U.S. operations and enabling entry into the high-entry-barrier U.S. government procurement market, including federal, veterans affairs, and military supply programs.

Our Emerging Markets business is on a steady trajectory as well. With the shift towards niche products, we are now at mid teens EBITDA Margin. Importantly, the Emerging Markets business is now cash flow positive.

All in all, we continue to outperform on our stated commitments despite an uncertain environment, reflecting the strength of our long-term strategy, diversified business verticals and disciplined execution. We remain confident in sustaining this momentum in the years ahead, led by robust product pipeline, expanded manufacturing capacities, and a strengthened R&D infrastructure.”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 51 ANDAs and 34 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 478 product registrations and over 904 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant, second in Gujarat, which is also US-FDA approved and the third in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to Emerging Markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899